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Human Recombinant Apyrase Therapy Protects Against 
Myocardial Ischemia/Reperfusion Injury and Preserves 
Left Ventricular Systolic Function in Rats, as Evaluated 
by 7T Cardiovascular Magnetic Resonance Imaging
Ziqian Xu, PhD1, Wei Chen, PhD2, Ruzhi Zhang, MD1, Lei Wang, BD1, Ridong Chen, PhD3,  
Jie Zheng, PhD4, Fabao Gao, MD, PhD1
1Department of Radiology, West China Hospital, Sichuan University, Chengdu, China; 2Department of Radiology, The First Affiliated Hospital of 
Kunming Medical College, Kunming, China; 3APT Therapeutics Inc., St Louis, MO, USA; 4Mallinckrodt Institute of Radiology, Washington University 
School of Medicine, St. Louis, MO, USA 
Objective: The occurrence of intramyocardial hemorrhage (IMH) and microvascular obstruction (MVO) in myocardial infarction 
(MI), known as severe ischemia/reperfusion injury (IRI), has been associated with adverse remodeling. APT102, a soluble 
human recombinant ecto-nucleoside triphosphate diphosphohydrolase-1, can hydrolyze extracellular nucleotides to attenuate 
their prothrombotic and proinflammatory effects. The purpose of this study was to temporally evaluate the therapeutic effect 
of APT102 on IRI in rats and to elucidate the evolution of IRI in the acute stage using cardiovascular magnetic resonance 
imaging (CMRI).
Materials and Methods: Fifty-four rats with MI, induced by ligation of the origin of the left anterior descending coronary 
artery for 60 minutes, were randomly divided into the APT102 (n = 27) or control (n = 27) group. Intravenous infusion of 
APT102 (0.3 mg/kg) or placebo was administered 15 minutes before reperfusion, and then 24 hours, 48 hours, 72 hours, 
and on day 4 after reperfusion. CMRI was performed at 24 hours, 48 hours, 72 hours, and on day 5 post-reperfusion using a 
7T system and the hearts were collected for histopathological examination. Cardiac function was quantified using cine 
imaging and IMH/edema using T2 mapping, and infarct/MVO using late gadolinium enhancement.
Results: The extent of infarction (p < 0.001), edema (p < 0.001), IMH (p = 0.013), and MVO (p = 0.049) was less severe in 
the APT102 group than in the control group. IMH size at 48 hours was significantly greater than that at 24 hours, 72 hours, 
and 5 days after reperfusion (all p < 0.001). The left ventricular ejection fraction (LVEF) was significantly greater in the 
APT102 group than in the control group (p = 0.006). There was a negative correlation between LVEF and IMH (r = -0.294, p = 
0.010) and a positive correlation between IMH and MVO (r = 0.392, p < 0.001).
Conclusion: APT102 can significantly alleviate damage to the ischemic myocardium and microvasculature. IMH size peaked 
at 48 hours post reperfusion and IMH is a downstream consequence of MVO. IMH may be a potential therapeutic target to 
prevent adverse remodeling in MI.
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250–270 g; age, 9–10 weeks) were subjected to ligation of 
the origin of the left anterior descending coronary artery 
for 60 minutes. Six rats died due to arrhythmia during the 
ischemic period; 54 rats were randomly assigned to either 
the APT102 (n = 27) or control (n = 27) group. APT102 
(0.3 mg/kg) or an equal concentration of a placebo was 
injected via the tail vein at 15 minutes before reperfusion, 
and then at 1, 2, 3, and 4 days afterward. The animal model 
of myocardial ischemia/reperfusion was established as 
previously described (16). All experimental procedures were 
approved by the experimental Animal Ethics Committee of 
West China Hospital, Sichuan University (Chengdu, China).
CMRI Protocols
CMRI was performed using a small animal 7T magnetic 
resonance imaging system (BioSpec 70/30; Bruker, 
Karlsruhe, Germany) equipped with a 4-channel rat heart 
surface coil. Rats were imaged on days 1, 2, 3, and 5 after 
reperfusion. The pre-scanning preparation was conducted as 
previously described (16). Gadopentetate dimeglumine (Gd-
DTPA, 0.15 mmol/kg; SA Instruments, Inc., Stony Brook, NY, 
USA) was injected through the tail vein and late gadolinium 
enhancement (LGE) imaging was performed 10 minutes 
after injection.
Images of the heart were obtained using a gradient-echo 
sequence. Gated multi-slice IntraGate Fast Low Angle Shot-
cine was then performed to confirm the heart position in 
three planes (short-axis, and 2- and 4-chamber long axis) 
to determine the location of the LV using the following 
scanning parameters: repetition time/echo time (TR/TE) = 
8 ms/3 ms, matrix (MTX) = 256 x 256, field of view (FOV) 
= 5 x 5 cm, and slice thickness = 1.5 mm. T2 mapping was 
acquired using a fast spin echo technique from the cardiac 
base to apex (scanning parameters: TR/TE = 1500 ms/10, 
20, and 30 ms, flip angle = 180°, acquisition MTX = 192 
x 192, FOV = 5 x 5 cm, number of slices = 6 or 7, slice 
thickness = 1.5 mm, and slice gap = 1.5 mm). LGE was 
acquired using a fast imaging with steady precession (FISP) 
technique (scanning parameters: TR/TE = 5.2 ms/1.8 ms, 
flip angle = 25°, no inversion recovery pulse, MTX = 256 x 
256, FOV = 5 x 5 cm, slice thickness = 1.5 mm, slice gap = 
1.5 mm). 
Histopathology
Rats were sacrificed at 24 hours (n = 5 for each group), 
48 hours (n = 5 for each), 72 hours (n = 5 for each), or 
on day 5 (n = 12 for each) after reperfusion. Hearts were 
INTRODUCTION
In patients with acute ST-segment elevation myocardial 
infarction (STEMI), timely myocardial reperfusion therapeutic 
methods can effectively salvage viable cardiomyocytes, limit 
the extent of myocardial infarction (MI), improve long-term 
myocardial function, reduce mortality, and prevent heart 
failure (1). However, the process of myocardial reperfusion 
can itself concurrently induce additional capillary damage 
and cardiomyocyte injury, a common phenomenon known 
as myocardial ischemia/reperfusion injury (IRI) (2), which 
may cause ventricular arrhythmia (3), myocardial stunning 
(4), microvascular obstruction (MVO) (5), intramyocardial 
hemorrhage (IMH) (6), and lethal myocardial reperfusion 
injury (7). Although the underlying mechanisms of IRI 
have not been completely elucidated, previous studies 
have found that MVO and IMH were independent predictors 
of larger infarct size, lower left ventricular (LV) systolic 
function, and major adverse cardiac events (8). Hence, early 
detection and preventive or active treatment of IMH and 
MVO may significantly influence clinical judgements and 
outcomes.
The extracellular nucleotides, adenosine triphosphate 
(ATP) and adenosine diphosphate (ADP), are released from 
injured cardiomyocytes into the extracellular interstitium 
where they bind to the purinergic receptors P2X and P2Y on 
platelets, endothelial cells, and immune cells, which then 
secrete prothrombotic and proinflammatory cytokines (9). 
Human ecto-nucleoside triphosphate diphosphohydrolase 
(E-NTPDase)-1 (CD39) is an extracellular apyrase that 
hydrolyzes ATP and ADP to adenosine monophosphate 
(AMP) and attenuates prothrombotic and proinflammatory 
effects without increasing bleeding risk, while CD39 activity 
is lost with prolonged IRI (10, 11). Previous studies have 
demonstrated that the administration of APT102, a soluble 
human recombinant CD39, can alleviate IRI following 
ischemic stroke (12), lung infarction (13), lung isografts 
(14), and MI (15). Therefore, the purpose of this study was 
to temporally evaluate the therapeutic effects of human 
recombinant apyrase APT102 on IRI in rats and to elucidate 
the evolution of IRI in the acute stage using cardiovascular 
magnetic resonance imaging (CMRI). 
MATERIALS AND METHODS
Animal Preparation
A total of 60 female Sprague-Dawley rats (weight, 
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explanted and fixed with 4% paraformaldehyde solution 
at 4°C for 48 hours. According to the scanning slices, the 
hearts were sectioned into consecutive 1.5-mm-thick slices 
along the short-axis plane. Each slice was photographed 
using a digital camera (D7500; Nikon Corporation, Tokyo, 
Japan) to register and quantify IMH. Hematoxylin and eosin 
(H&E) staining was used to qualitatively assess necrosis, 
inflammation, IMH, and MVO. Two observers with at least 5 
years’ experience in pathological examination blinded to the 
CMR images and groups separately analyzed all gross slides 
and histopathologic images. Disagreements were resolved 
by consensus.
Data Analysis
Two radiologists with a minimum of 7 years related 
experience, blinded to the pathology results and group 
distributions, analyzed all CMR images and calculated 
averages. Three T2 images (TE = 10, 20, and 30 ms) were 
amalgamated using custom software written in MATLAB 
(version 7.1; MathWorks, Natick, MA, USA). On T2 mapping 
images, the area of myocardial edema was defined as a 
mean signal intensity threshold of two standard deviations 
(SDs) above the mean remote myocardium (17) and IMH 
was defined as a hypointense core within a hyperintense 
area (18). Meanwhile, on LGE images, MI was defined and 
quantified as an area with a mean signal intensity at least 
5 SDs above the remote myocardium (19). MVO was defined 
as the non-contrasted enhancement zone within the infarct 
region (20). The example analysis of these parameters is 
shown in Supplementary Figure 1. All parameters were 
manually measured using ImageJ software (National 
Institutes of Health, Bethesda, MD, USA). The epicardial 
and endocardial outlines (papillary muscles were excluded 
from the endocardium) at left ventricular end-diastole and 
left ventricular end-systole were manually drawn on cine 
images, slice by slice. The left ventricular myocardial volume 
(LVMV), left ventricular end-diastolic volume (LVEDV), left 
ventricular end-systolic volume (LVESV), stroke volume 
(SV), and left ventricular ejection fraction (LVEF) were then 
calculated by multiplying the slice thickness and slice gap. 
The total volume of MI, edema, IMH, and MVO in cubic 
centimeters was calculated by multiplying the area by the 
slice thickness and slice gap and expressed as a percentage 
of LVMV.
Statistical Analysis
Quantitative data were tested for normal distribution 
using the Kolmogorov-Smirnov test. Levene’s test was used 
to assess the homogeneity of variance. Time sequential 
changes in T2 values and the extent of edema, IMH, MI, 
and MVO, as well as cardiac function were evaluated using 
two-way repeated measures analyses of variance with the 
least significance difference and post hoc Bonferroni’s 
test for multiple comparisons. The Greenhouse–Geisser 
correction was applied when Mauchley’s test indicated 
that the assumption of sphericity had been violated. The 
partial correlation between LVEF and the extent of MI, 
edema, IMH, and MVO was assessed. All statistical analyses 
were performed using SPSS Statistics version 23.0 (IBM 
Corp., Armonk, NY, USA). Interobserver and intraobserver 
agreement was calculated using the intraclass correlation 
coefficient. Limits of agreement for IMH size between 
the T2 mapping and the gross pathology images were 
determined using Bland-Altman analysis performed on 
Prism (version 7.0; GraphPad, San Diego, CA, USA). Data are 
expressed as the mean ± SD or as numbers (percentages). A 
probability (p) value of < 0.05 was considered statistically 
significant.
RESULTS
One rat in the control group died of respiratory failure 
during scanning. Scanning images from one rat in the 
control group and two rats in the APT102 group contained 
motion artifacts and could not be analyzed and were thus 
excluded from the analysis. A flow chart is shown in Figure 1. 
APT102 Reduced MI Size
The infarct size was significantly smaller in the APT102 
group than in the control group (F = 23.627, p < 0.001) 
(Table 1). There were significant main effects at all time 
points (F = 143.011, p < 0.001) (Table 1), but no significant 
interactions between groups and time points (F = 1.017, p = 
0.361) (Table 1). Infarct size at 24 hours was significantly 
greater than at 48 hours, 72 hours, and on day 5 (p = 0.008, 
p < 0.001, and p < 0.001, respectively) (Table 1, Fig. 2A) 
after reperfusion. The infarct size was significantly smaller 
in the APT102 group than in the control group at 24 hours 
(18.0 ± 4.8% vs. 26.7 ± 5.7%, respectively, p = 0.002), 
48 hours (17.1 ± 4.3% vs. 25.7 ± 6.0%, respectively, 
p = 0.002), 72 hours (11.6 ± 2.6% vs. 21.5 ± 6.0%, 
respectively, p < 0.001), and on day 5 (5.8 ± 1.5% vs. 16.2 





Table 1. Comparison of Myocardial Characterization according to Time Points and Groups
Variable 24 h 48 h 72 h Day 5
Group Time Group x Time
F P F P F P
Infarct size (%)
Control (n = 10) 26.7 ± 5.7 25.7 ± 6.0 21.5 ± 6.0 16.2 ± 4.0
23.627 < 0.001 143.011 < 0.001 1.017 0.361
APT102 (n = 10) 18.0 ± 4.8 17.1 ± 4.3 11.6 ± 2.6 5.8 ± 1.5
Edema size (%)
Control (n = 10) 30.2 ± 4.4 30.8 ± 3.9 26.8 ± 3.5 20.0 ± 2.5
19.016 < 0.001 115.878 < 0.001 1.780 0.190
APT102 (n = 10) 24.0 ± 5.0 24.4 ± 6.5 18.2 ± 4.8 11.2 ± 2.9
IMH size (%)
Control (n = 10) 3.9 ± 2.0 5.2 ± 2.3 3.7 ± 1.5 2.7 ± 1.1
7.646 0.013 35.742 < 0.001 0.115 0.886
APT102 (n = 10) 2.3 ± 1.3 3.4 ± 1.8 2.1 ± 1.1 0.9 ± 0.6
MVO size (%)
Control (n = 10) 3.8 ± 0.8 3.1 ± 0.9 2.3 ± 0.6 1.0 ± 0.3
4.444 0.049 175.394 < 0.001 0.735 0.463
APT102 (n = 10) 3.3 ± 0.8 2.7 ± 0.7 1.7 ± 0.5 0.6 ± 0.3
LVMV (mm3)
Control (n = 10) 8.8 ± 1.0 8.8 ± 1.0 8.5 ± 1.0 8.2 ± 1.0
0.122 0.731 22.642 < 0.001 0.695 0.487
APT102 (n = 10) 8.6 ± 0.8 8.6 ± 1.0 8.4 ± 0.9 8.1 ± 0.8
IMH = intramyocardial hemorrhage, LV = left ventricular, LVMV = left ventricular myocardial volume, MVO = microvascular obstruction
Fig. 1. Flow chart of study protocol. CMR = cardiovascular magnetic resonance, IR = ischemia/reperfusion, LAD = left anterior descending 
branch, RF = respiratory failure
60 min LAD ligation
(n = 60)
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APT102 Reduced Myocardial Edema Size
The edema size was significantly smaller in the APT102 
group than in the control group (F = 19.016, p < 0.001) 
(Table 1). There were significant main effects at all time 
points (F = 115.878, p < 0.001) (Table 1), but no significant 
interactions between groups and time points (F = 1.780, p = 
0.190) (Table 1). The extent of edema at 24 hours and 48 
hours was significantly greater than that at 72 hours (both 
p < 0.001) (Fig. 2B) and on day 5 (both p < 0.001) (Fig. 2B) 
after reperfusion, and there was no significant difference in 
edema size between 24 hours and 48 hours after reperfusion 
(p = 0.277) (Fig. 2B). When compared with that in the 
control group, the extent of edema was significantly less 
in the APT102 group at 24 hours (24.0 ± 5.0% vs. 30.2 ± 
4.4%, respectively, p = 0.007), 48 hours (24.4 ± 6.5% vs. 
30.8 ± 3.9%, respectively, p = 0.016), 72 hours (18.2 ± 4.8% 
vs. 26.8 ± 3.5%, respectively, p < 0.001), and on day 5 
(11.2 ± 2.9% vs. 20.0 ± 2.5%, respectively, p < 0.001) after 
Fig. 2. Temporal evolution of myocardial characterization and left ventricular function in control and APT102 groups. *p < 0.05, 
**p < 0.01, ***p < 0.001, †p > 0.05. IMH = intramyocardial hemorrhage, LVEF = left ventricular ejection fraction, LVESV = left ventricular end-



































































































































































































after reperfusion, while there was no significant difference 
at 48 hours (3.4 ± 1.8% vs. 5.2 ± 2.3%, p = 0.068) after 
reperfusion, as shown in Figure 2C. Figure 3 shows CMR 
images from one APT102 rat and one control rat at four 
time points after reperfusion showing the extent of IMH and 
MVO, and the persistently elevated T2 in the surrounding 
myocardium within the infarct zone.
APT102 Reduced MVO Size
There were significant differences in MVO size between 
the APT102 and control groups (F = 4.444, p = 0.049) 
(Table 1). The extent of MVO was significantly greater at 
24 hours after reperfusion than at 48 hours, 72 hours, and 
on day 5 (all p < 0.001) (Table 1, Fig. 2D). The extent of 
MVO was significantly less in the APT102 group than in 
the control group at 72 hours (1.7 ± 0.5% vs. 2.3 ± 0.6%, 
respectively, p = 0.038) and on day 5 (0.6 ± 0.3% vs. 1.0 
reperfusion, as shown in Figure 2B.
APT102 Reduced IMH Size
The extent of IMH was significantly less in the APT102 
group than in the control group (F = 7.646, p = 0.013) 
(Table 1). There were significant main effects at all time 
points (F = 35.742, p < 0.001) (Table 1), but no significant 
interactions between groups and time points (F = 0.115, 
p = 0.886) (Table 1). IMH size at 48 hours was significantly 
greater than at 24 hours, 72 hours, and on day 5 (all p < 
0.001) (Table 1, Fig. 2C) after reperfusion, which confirmed 
that the extent of IMH peaked at 48 hours after reperfusion. 
Additionally, the extent of IMH was significantly less in the 
APT102 group than in the control group at 24 hours (2.3 ± 
1.3% vs. 3.9 ± 2.0%, respectively, p = 0.040), 72 hours (2.1 
± 1.1% vs. 3.7 ± 1.5%, respectively, p = 0.014), and on 
day 5 (0.9 ± 0.6% vs. 2.7 ± 1.1%, respectively, p < 0.001) 
Fig. 3. Sequential changes in CMR images from one control subject (A) and one APT102 subject (B). Red dotted lines show areas of 
IMH on T2 maps and yellow dotted lines show areas of MVO on LGE images. LGE = late gadolinium enhancement
T2
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± 0.3%, respectively, p = 0.021) after reperfusion, whereas 
there was no significant difference at 24 hours (3.3 ± 
0.8% vs. 3.8 ± 0.8%, respectively, p = 0.146) or 48 hours 
(2.7 ± 0.7% vs. 3.1 ± 0.9%, respectively, p = 0.256) after 
reperfusion, as shown in Figure 2D.
APT102 Enhanced LV Systolic Function
LVEF was significantly greater in the APT102 group than 
in the control group (F = 9.708, p = 0.006) (Table 2). LVEF 
at 48 hours after reperfusion was significantly greater than 
at 24 hours, 72 hours, and on day 5, which demonstrates 
that LVEF peaked at 48 hours after reperfusion, as shown 
in Figure 2E. LVESV was significantly lower in the APT102 
than in the control group (F = 7.046, p = 0.016) (Table 2). 
Moreover, there was no significant difference in LVEDV (F = 
1.058, p = 0.317) (Table 2) or SV (F = 0.335, p = 0.570) 
(Table 2) between the two groups. The representative cine 
images from 24 hours and on day 5 after reperfusion from 
both groups are shown in Supplementary Movie 1.
Temporal Evolution of T2 Values of Myocardial Edema, 
IMH, and Remote Zones
There were no significance differences in the T2 values of 
the remote myocardium, myocardial edema, or IMH between 
the APT102 and control groups. However, the T2 value of 
the myocardial edema at 48 hours was significantly greater 
than at 24 hours, 72 hours, and on day 5 after reperfusion. 
The T2 value of IMH on day 5 after reperfusion was 
significantly lower than at 24 hours, 48 hours, and 72 hours 
after reperfusion (Table 3, Fig. 2G, H).
Relationship between MI, IMH, MVO, and LVEF
Intra- and interobserver reliability of the measurement of 
the infarct, edema IMH, and MVO area is shown in Table 4. 
Fig. 3. Sequential changes in CMR images from one control subject (A) and one APT102 subject (B). Red dotted lines show areas of 
IMH on T2 maps and yellow dotted lines show areas of MVO on LGE images. LGE = late gadolinium enhancement
T2



















Bland-Altman plots showed that the volume of IMH 
measured on T2 mapping images matched well with the 
gross pathology images (Fig. 5). Figure 6 shows the CMR 
images and corresponding slices of the gross pathologic 
images, as well as H&E-stained images of the heart sections 
from representative subjects. The distinct red to reddish 
black areas on gross sections were defined as areas of 
IMH, where red blood cells and inflammatory cells caused 
swelling of the myocardial interstitium.
DISCUSSION
It is well known that there is a strong association 
between the extent of MVO and IMH with a reported 
correlation coefficient of IMH of 0.80–0.87 for late MVO 
(21, 22). Likewise, there was also a positive correlation in 
the present study (r = 0.392). We observed that the extent 
There was a significant and negative correlation between 
LVEF and MI size (r = -0.230, p = 0.046), and IMH size 
(r = -0.294, p = 0.010), and a significant and positive 
correlation between IMH size and MVO size (r = 0.392, p < 
0.001), while no significant correlation was found between 
LVEF and edema size (r = 0.184, p = 0.112), and MVO size  
(r = 0.065, p = 0.574), as shown in Figure 4.
Table 2. Comparison of LV Systolic Function according to Time Points and Groups
Variable 24 h 48 h 72 h Day 5
Group Time Group x Time
F P F P F P
LVEDV (mL)
Control (n = 10) 6.2 ± 0.6 6.2 ± 0.6 6.4 ± 0.7 6.6 ± 0.8
1.058 0.317 10.439 < 0.001 2.008 0.147
APT102 (n = 10) 5.9 ± 0.8 5.9 ± 0.8 6.1 ± 0.8 6.1 ± 1.0
LVESV (mL)
Control (n = 10) 2.6 ± 0.5 2.5 ± 0.4 2.9 ± 0.4 3.3 ± 0.5
7.046 0.016 31.465 < 0.001 21.065 < 0.001
APT102 (n = 10) 2.5 ± 0.3 2.2 ± 0.3 2.3 ± 0.4 2.4 ± 0.5
SV (mL)
Control (n = 10) 3.5 ± 0.4 3.7 ± 0.4 3.6 ± 0.4 3.3 ± 0.6
0.335 0.570 6.912 0.003 5.372 0.009
APT102 (n = 10) 3.5 ± 0.7 3.7 ± 0.6 3.8 ± 0.5 3.7 ± 0.6
LVEF (%)
Control (n = 10) 57.5 ± 4.4 60.2 ± 4.8 55.7 ± 3.8 49.5 ± 6.4
9.708 0.006 23.765 < 0.001 21.202 < 0.001
APT102 (n = 10) 58.1 ± 4.4 62.9 ± 3.5 62.5 ± 3.5 61.2 ± 3.9
LVEDV = left ventricular end-diastolic volume, LVEF = left ventricular ejection fraction, LVESV = left ventricular end-systolic volume, SV = 
stroke volume
Table 3. Comparison of T2 Value according to Time Points and Groups
Variable 24 h 48 h 72 h Day 5
Group Time Group x Time
F P F P F P
Remote T2 values (ms)
Control (n = 10) 22.4 ± 0.6 22.3 ± 0.4 22.5 ± 0.4 22.3 ± 0.5
2.206 0.155 0.056 0.982 0.351 0.784
APT102 (n = 10) 22.1 ± 0.5 22.2 ± 0.6 22.1 ± 0.4 22.2 ± 0.7
Edema T2 values (ms)
Control (n = 10) 38.8 ± 1.5 43.7 ± 2.7 41.1 ± 3.4 36.5 ± 2.6
1.320 0.266 37.400 < 0.001 0.462 0.620
APT102 (n = 10) 38.7 ± 2.8 42.8 ± 3.1 39.5 ± 2.3 35.5 ± 1.5
IMH T2 values (ms)
Control (n = 10) 28.9 ± 2.2 29.3 ± 1.7 28.6 ± 2.7 25.1 ± 1.3
0.713 0.410 23.055 < 0.001 0.462 0.710
APT102 (n = 10) 27.8 ± 1.4 28.3 ± 3.1 28.0 ± 2.3 25.5 ± 1.7
Table 4. Intra- and Interobserver Reliability of Measurement 





Infarct size 0.973 (0.956–0.983) 0.942 (0.906–0.964)
Edema size 0.963 (0.932–0.978) 0.855 (0.761–0.911)
IMH size 0.987 (0.980–0.992) 0.943 (0.912–0.963)
MVO size 0.980 (0.969–0.987) 0.927 (0.888–0.952)
CI = confidence interval, ICC = intraclass correlation coefficient
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of MVO peaked at 24 hours after reperfusion and decreased 
thereafter, while IMH size peaked at 48 hours after 
reperfusion and then decreased thereafter. The observed 
temporal evolution of IMH and MVO was consistent with 
the clinical study by Carrick et al. (23), where MVO peaked 
at 4 to 12 hours post reperfusion, whereas IMH increased 
Fig. 4. Linear correlation between extent of MI, IMH, MVO, and LVEF. There was negative correlation between LVEF and MI size (A), and 
IMH size (C), and positive correlation between IMH size and MVO size (E), while no significant correlation was found between LVEF and edema 






























































































progressively and peaked at 72 hours post reperfusion. 
The results of that study and the present study indicated 
that MVO almost precedes IMH in the temporal evolution 
of IRI and IMH is the downstream consequence of MVO. 
Furthermore, the extent of IMH was approximately equal to 
or greater than that of MVO at different time points, and 
regions of late MVO almost coincided with regions of IMH. 
Because of the slow diffusion of Gd-DTPA over time around 
the periphery of no-flow regions, the extent of MVO seen on 
LGE may be smaller than that on either first pass perfusion 
or early gadolinium enhancement (24). Furthermore, FISP-
cine with a relatively long acquisition time in the present 
study may have also contributed to the underestimation 
of the extent of MVO (16). Previous studies using canine 
and porcine models with 90-minute occlusion of the left 
anterior descending branch have demonstrated an almost 
3-fold increase in MVO size over the first 48 hours post 
reperfusion (25), while our data showed that MVO peaked 
Fig. 5. Comparison of IMH size on day 5 after reperfusion 
as measured using T2 mapping with pathological gross 
examination. Bland-Altman plot shows that IMH size measured using 
T2 mapping and pathological gross examination were not significantly 
different (mean difference 0.0008%, 95% limit of agreement from 
-0.3019% to 0.3036%). LVMV = left ventricular myocardial volume, 
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Fig. 6. CMR images and corresponding pathology at four time points after reperfusion of control subjects (A) and APT102 
subjects (B). Red arrows show areas of IMH on T2 maps and gross sections and white arrows show areas of MVO on LGE images. H&E = 
hematoxylin and eosin
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at 24 hours post reperfusion, which may be ascribed to the 
different occlusion times of the left anterior descending 
branch and differences in animal models.
A great number of studies (23, 26-28) have provided 
strong evidence that IMH and residual myocardial iron 
are adverse prognostic complications in reperfused STEMI 
patients and porcine models. In this study, a negative 
correlation was also demonstrated between IMH and LVEF 
(r = -0.294). Thus, IMH may be a potential therapeutic 
target for the prevention of adverse LV remodeling and the 
occurrence time of IMH suggests a therapeutic window may 
exist to efficiently prevent IMH. Human E-NTPDase-1/CD39 
is an extracellular nucleotide that hydrolyzes extracellular 
ATP and ADP to AMP, which is converted to adenosine 
by CD73 (11, 29). In addition, CD39 can impede ATP and 
ADP interactions at platelet P2 receptors (11). Thus, CD39 
could efficiently inhibit inflammation and thrombosis while 
maintaining vascular integrity. Köhler et al. (15) suggested 
that ischemic preconditioning with brief cycles of short-
term coronary occlusion and reperfusion performed before 
prolonged coronary artery occlusion with reperfusion 
could increase the expression of CD39 by the endothelia 
and myocytes and reduce infarct size, while this work did 
not report a powerful effect on IMH and MVO (15). In 
the present study, APT102 not only reduced the extent of 
infarction and edema, but also the extent of IMH and MVO, 
which has not been reported before.
In the present study, the mean T2 values of myocardial 
edema at 24 hours and 48 hours after reperfusion were 38.8 
± 1.5 ms and 43.7 ± 2.7 ms in the control group, which 
were close to the values of 34.7 ± 6.7 ms and 47.7 ± 6.6 
ms acquired in previous studies (16, 30, 31). The mean T2 
value of IMH at 48 hours (29.3 ± 1.7 ms) was also similar 
to that in a previous study (27.6 ± 3.3 ms) (16), where T2 
values of remote myocardium were greater (22.3 ± 0.4 ms) 
but lower than those of edema (43.7 ± 2.7 ms), reflecting 
Fig. 6. CMR images and corresponding pathology at four time points after reperfusion of control subjects (A) and APT102 
subjects (B). Red arrows show areas of IMH on T2 maps and gross sections and white arrows show areas of MVO on LGE images. H&E = 
hematoxylin and eosin









































1. Keeley EC, Boura JA, Grines CL. Comparison of primary and 
facilitated percutaneous coronary interventions for ST-
elevation myocardial infarction: quantitative review of 
randomised trials. Lancet 2006;367:579-588
2. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N 
Engl J Med 2007;357:1121-1135
3. Hearse DJ, Tosaki A. Free radicals and reperfusion-induced 
arrhythmias: protection by spin trap agent PBN in the rat 
heart. Circ Res 1987;60:375-383
4. Kloner RA, Bolli R, Marban E, Reinlib L, Braunwald E. 
Medical and cellular implications of stunning, hibernation, 
and preconditioning: an NHLBI workshop. Circulation 
1998;97:1848-1867
5. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, 
Schulman SP, et al. Prognostic significance of microvascular 
obstruction by magnetic resonance imaging in patients with 
acute myocardial infarction. Circulation 1998;97:765-772
6. Ochiai K, Shimada T, Murakami Y, Ishibashi Y, Sano K, 
Kitamura J, et al. Hemorrhagic myocardial infarction after 
coronary reperfusion detected in vivo by magnetic resonance 
imaging in humans: prevalence and clinical implications. J 
Cardiovasc Magn Reson 1999;1:247-256
7. Piper HM, García-Dorado D, Ovize M. A fresh look at 
reperfusion injury. Cardiovasc Res 1998;38:291-300
8. Hamirani YS, Wong A, Kramer CM, Salerno M. Effect of 
microvascular obstruction and intramyocardial hemorrhage 
by CMR on LV remodeling and outcomes after myocardial 
infarction: a systematic review and meta-analysis. JACC 
Cardiovasc Imaging 2014;7:940-952
9. Cauwels A, Rogge E, Vandendriessche B, Shiva S, Brouckaert P. 
Extracellular ATP drives systemic inflammation, tissue damage 
and mortality. Cell Death Dis 2014;5:e1102
10. Smith SB, Xu Z, Novitskaya T, Zhang B, Chepurko E, Pu XA, 
et al. Impact of cardiac-specific expression of CD39 on 
myocardial infarct size in mice. Life Sci 2017;179:54-59
11. Moeckel D, Jeong SS, Sun X, Broekman MJ, Nguyen A, 
Drosopoulos JHF, et al. Optimizing human apyrase to treat 
arterial thrombosis and limit reperfusion injury without 
increasing bleeding risk. Sci Transl Med 2014;6:248ra105
12. Tan Z, Li X, Turner RC, Logsdon AF, Lucke-Wold B, DiPasquale 
K, et al. Combination treatment of r-tPA and an optimized 
human apyrase reduces mortality rate and hemorrhagic 
transformation 6h after ischemic stroke in aged female rats. 
Eur J Pharmacol 2014;738:368-373
13. Ibrahim M, Wang X, Puyo CA, Montecalvo A, Huang HJ, 
Hachem RR, et al. Human recombinant apyrase therapy 
protects against canine pulmonary ischemia-reperfusion 
injury. J Heart Lung Transplant 2015;34:247-253
14. Sugimoto S, Lin X, Lai J, Okazaki M, Das NA, Li W, et al. 
Apyrase treatment prevents ischemia-reperfusion injury in rat 
lung isografts. J Thorac Cardiovasc Surg 2009;138:752-759
15. Köhler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S, 
the contrasting effects of hemorrhage, which tends to 
shorten T2, with that of edema, which increases T2 (16, 32). 
Lastly, there was an apparent discrepancy between the 
delayed recovery of LV systolic function and the maximal 
extent of IMH and edema at 48 hours post reperfusion in 
the APT102 and control groups. Our data disclosed that 
LVEF at 48 hours was greater than that at 24 hours, while 
LVESV was lower than that at 24 hours. This phenomenon 
can be explained by the delay in functional recovery of the 
salvaged myocardium, where stunning can occur. Myocardial 
stunning is a reversible injury where postischemic 
myocardial function can recover to preischemic levels upon 
reperfusion (33). 
Supplementary Materials
The Data Supplement is available with this article at 
https://doi.org/10.3348/kjr.2019.0853.
Supplementary Movie Legends
Movie 1. Representative cine images from 24 hours and 
on day 5 after reperfusion from control subjects (A) and 
APT102 subjects (B).
The infarcted wall of the control subject is thinner than 
the APT102 subject, and the wall contraction of the control 
subject is weaker than the APT102 subject.
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